Trial Profile
A Phase II Study of Adjuvant PALbociclib as an Alternative to CHemotherapy in Elderly patientS With High-risk ER+/HER2- Early Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2024
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Paclitaxel
- Indications Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms APPALACHES
- 23 Jan 2024 Planned primary completion date changed from 30 Sep 2027 to 30 Jun 2026.
- 16 Nov 2022 Planned End Date changed from 13 Sep 2032 to 30 Sep 2032.
- 16 Nov 2022 Planned primary completion date changed from 13 Sep 2027 to 30 Sep 2027.